Peter le Witt, MD
Neurology · West Bloomfield, MINPI 1750434114
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by MDD US Operations, LLC at 33.3% of the total. Reporting peaked in 2019 at $127,828 and has fallen 63.3% since, to $46,859 in 2025. Among neurology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 401 payments — averaging $930.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$124K
- Acorda Therapeutics, Inc$69K
- Kyowa Kirin, Inc.$69K
- Amneal Pharmaceuticals LLC$36K
- Neurocrine Biosciences, Inc.$17K
- Otsuka America Pharmaceutical, Inc.$14K
- plus $44K from 21 others
Across 311 payments — averaging $9044.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$999K
- Roche TCRC, Inc.$740K
- H. Lundbeck A S$545K
- Amneal Pharmaceuticals LLC$299K
- Sunovion Pharmaceuticals Inc.$122K
- MDD US Operations, LLC$73K
- plus $35K from 4 others
What the payments were for
- Consulting fees$134,32136%
- Speaking & faculty fees$201,51554%
- Travel & lodging$28,7378%
- Food & beverage$8,5932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 192 | $124,361 |
| Acorda Therapeutics, Inc | 28 | $69,089 |
| Kyowa Kirin, Inc. | 66 | $69,072 |
| Amneal Pharmaceuticals LLC | 32 | $35,635 |
| Neurocrine Biosciences, Inc. | 23 | $16,850 |
| Otsuka America Pharmaceutical, Inc. | 3 | $13,961 |
| Jazz Pharmaceuticals Inc. | 4 | $9,700 |
| Biogen | 9 | $8,046 |
| Acadia Pharmaceuticals Inc | 5 | $7,370 |
| H. Lundbeck A S | 2 | $5,557 |
| Genentech, Inc. | 3 | $4,095 |
| Lundbeck LLC | 1 | $2,000 |
| Bayer | 10 | $1,617 |
| Supernus Pharmaceuticals, Inc. | 1 | $1,500 |
| Sage Therapeutics, LLC | 1 | $1,170 |
| Sunovion Pharmaceuticals Inc. | 1 | $623 |
| Tolmar, Inc. | 1 | $500 |
| AbbVie | 7 | $480 |
| Vertex | 1 | $427 |
| Dr.reddy's Laboratories,inc. | 1 | $347 |
| Boston Scientific | 2 | $201 |
| Ipsen Biopharmaceuticals, Inc | 3 | $149 |
| Merz North America, Inc. | 1 | $148 |
| GE HealthCare | 1 | $109 |
| Alnylam Pharmaceuticals Inc. | 1 | $107 |
| UCB, Inc. | 1 | $31 |
| CSL Behring | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$373,166 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $168,468 |
| RytaryCarbidopa/Levodopa | 20 | $37,618 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 265 | $13,764 |
| Entacapone | 12 | $4,137 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 27 | $3,405 |
| AmantadineAmantadine Hcl | 37 | $1,613 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 12 | $1,118 |
| Propranolol Hcl ErPropranolol Hcl | 25 | $1,008 |
| Primidone | 31 | $985 |
| Quetiapine Fumarate | 40 | $776 |
| Ropinirole Hcl | 15 | $371 |
| Baclofen | 25 | $334 |
| Clonazepam | 20 | $231 |
| Donepezil Hcl | 13 | $175 |
| Trihexyphenidyl Hcl | 12 | $143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $16,850 | $168,46820 claims |
| Amneal Pharmaceuticals LLCRytary | $35,635 | $37,61820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.
Other neurology in West Bloomfield
- Steven SchechterWest Bloomfield$149K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
- Amit MasihOkemos$785K
- Martin BelkinFarmington Hills$712K
- Robert PaceOwosso$693K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.